The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
- Ricky M. Trigg
- , Liam C. Lee
- , Nina Prokoph
- , Leila Jahangiri
- , C. Patrick Reynolds
- , G. A. Amos Burke
- , Nicola A. Probst
- , Miaojun Han
- , Jamie D. Matthews
- , Hong Kai Lim
- , Eleanor Manners
- , Sonia Martinez
- , Joaquin Pastor
- , Carmen Blanco-Aparicio
- , Olaf Merkel
- , Ines Garces de los Fayos Alonso
- , Petra Kodajova
- , Simone Tangermann
- , Sandra Högler
- , Ji Luo
*Corresponding author for this work
- University of Cambridge
- GlaxoSmithKline
- Amgen Incorporated
- Texas Tech University Health Sciences Center
- Cambridge University Hospitals NHS Foundation Trust
- OncoSec Inc.
- Instituto de Salud Carlos III
- Medical University of Vienna
- University of Veterinary Medicine Vienna
- National Institutes of Health
Research output: Contribution to journal › Article › peer-review
37
Citations
(SciVal)